BioSpace News Archive

- Application Seeks to Expand VRAYLAR Indication to Include the Treatment of Bipolar Depression

Study enables clinical development in complement-mediated renal disorders

The new approximately 170,000 square foot facility will support more than 1,500 employees, including a state-of-the-art pharmacy facility, enhanced software and data science labs, and office space.

To Date, 61,000 Youth Educated Nationwide on Opioid Misuse and Abuse

Achieve Life Sciences, Inc. today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference being held Tuesday, October 2nd in New York City at the Sofitel Hotel New York.

Aldeyra Therapeutics Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it intends to offer and sell, subject to market and other conditions, 5,250,000 shares of its common stock in an underwritten public offering.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today provided an update on advancements to its pipeline programs.

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology, Oct. 3, 2018, at 10:30 am ET.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that it will redeem $125 million aggregate principal amount of its outstanding 7.50% Senior Notes due 2021, CUSIP Nos. 92912EAA1, C96715AA2 (the “Notes”) on Oct. 26, 2018.

Congratulations go out to the Lupus Research Alliance advocates!